Literature DB >> 25400009

Efficacy of ablative fractional laser-assisted photodynamic therapy for the treatment of actinic cheilitis: 12-month follow-up results of a prospective, randomized, comparative trial.

S H Choi1, K H Kim1, K-H Song1.   

Abstract

BACKGROUND: Early identification and treatment of actinic cheilitis (AC) is recommended. Although photodynamic therapy (PDT) is an attractive therapeutic option for AC, PDT for AC does not result in the same satisfactory outcomes as in actinic keratosis (AK).
OBJECTIVES: The aim of our study was to compare efficacy, recurrence rate, cosmetic outcome and safety between erbium:yttrium-aluminium-garnet ablative fractional laser-assisted methyl aminolaevulinate-PDT (Er:YAG AFL MAL-PDT) and standard MAL-PDT.
METHODS: Thirty-three patients with histologically confirmed AC randomly received either one session of Er:YAG AFL MAL-PDT or two sessions of MAL-PDT. In the MAL-PDT group, the second session of MAL-PDT was administered 7 days later. Patients were followed up at 1 week and 3 and 12 months, and biopsies were taken from all patients at 3 and 12 months after the last treatment session. At the final 12-month follow-up, cosmetic outcomes were assessed. Adverse events were assessed at week 1 of the treatment phase and every subsequent follow-up visit.
RESULTS: In the per-protocol (PP) population, Er:YAG AFL MAL-PDT was significantly more effective (92% complete response rate) than MAL-PDT (59%; P = 0.040) at the 3-month follow-up, and differences in efficacy remained significant at the 12-month follow-up (85% in Er:YAG AFL MAL-PDT and 29% in MAL-PDT). The recurrence rate was significantly lower for Er:YAG AFL MAL-PDT (8%) than for MAL-PDT (50%) group at 12 months (P = 0.029). No significant difference in cosmetic outcome or safety was observed between Er:YAG AFL MAL-PDT and MAL-PDT.
CONCLUSIONS: Ablative fractional laser pretreatment has significant benefit for the treatment of AC with PDT.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25400009     DOI: 10.1111/bjd.13542

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Laser-assisted drug delivery in dermatology: from animal models to clinical practice.

Authors:  Faisal R Ali; Firas Al-Niaimi
Journal:  Lasers Med Sci       Date:  2015-12-22       Impact factor: 3.161

2.  Comparative analysis of the effects of CO2 fractional laser and sonophoresis on human skin penetration with 5-aminolevulinic acid.

Authors:  J H Choi; E J Shin; K H Jeong; M K Shin
Journal:  Lasers Med Sci       Date:  2017-08-19       Impact factor: 3.161

3.  Evaluation of effect of a vitamin-based barrier cream on the clinical severity of actinic cheilitis: A preliminary study.

Authors:  Mariana-Sudati Rodrigues; Eduardo-Oliveira Kaefer; Juliana-Tomaz Sganzerla; Humberto-Thomazi Gassen; Rubem-Beraldo Dos Santos; Sergio-Augusto-Quevedo Miguens-Jr
Journal:  J Clin Exp Dent       Date:  2020-10-01

Review 4.  Laser Therapy for the Treatment of Actinic Cheilitis: A Systematic Review.

Authors:  Angela Ayen-Rodriguez; Maria Jose Naranjo-Diaz; Ricardo Ruiz-Villaverde
Journal:  Int J Environ Res Public Health       Date:  2022-04-11       Impact factor: 4.614

5.  Randomized Clinical Trial of Conventional versus Indoor Daylight Photodynamic Therapy for Treatment of Actinic Cheilitis.

Authors:  Mariachiara Arisi; Benedetta Galli; Edoardo Guasco Pisani; Giuseppe La Rosa; Gaetano Licata; Sara Rovaris; Cesare Tomasi; Mariateresa Rossi; Marina Venturini; Luigi Spiazzi; PierGiacomo Calzavara-Pinton
Journal:  Dermatol Ther (Heidelb)       Date:  2022-07-30

6.  Daylight photodynamic therapy for the management of actinic cheilitis.

Authors:  Dimitrios Andreadis; Achilleia -Maria Pavlou; Efstratios Vakirlis; Eleftherios Anagnostou; Fotini Vrani; Athanasios Poulopoulos; Alexandros Kolokotronis; Dimitrios Ioannidis; Elena Sotiriou
Journal:  Arch Dermatol Res       Date:  2020-04-07       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.